A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most common form of metastatic breast cancer.

References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...

Enhertu, the blockbuster antibody-drug conjugate discovered by Daiichi Sankyo and co-developed by AstraZeneca, was approved in the U.S. to treat any patient with advanced, HER2-positive cancer ...

Enhertu has been called a breakthrough in breast cancer treatment. While it doesn’t cure HER2 breast cancer, research shows that it provides patients with more time. According to the National Library ...

The safety of ENHERTU was evaluated in 101 patients with unresectable or metastatic HER2-mutant NSCLC who received ENHERTU 5.4 mg/kg intravenously every three weeks in DESTINY‑Lung02.